Published Date : 03 Jul 2023
The global single-photon emission computed tomography (SPECT) market size exceeded USD 2.78 billion in 2022 and is expected to hold around USD 5.31 billion by 2032, expanding at a CAGR of 6.69% during the forecast period 2023 to 2032.
An imaging examination that demonstrates how blood flows to tissues and organs is called a single photon emission computed tomography (SPECT) scan. Seizures, strokes, infections, stress fractures, and spinal tumors can all be identified with its aid. Medical imaging technology, single photon emission computed tomography (SPECT), is based on tomographic reconstruction techniques and traditional nuclear medicine imaging. Like positron emission tomography (PET), the pictures show helpful information about the patients. In contrast to other medical imaging modalities utilized for clinical diagnostic purposes, SPECT and PET offer data depending on the spatial concentration of administered radiopharmaceuticals.
The region of North America holds the largest share of the market. The rising number of cancer cases and the presence of prominent market players will lead to the market's growth. The increasing adoption of advanced medical imaging technologies and growing investments in the healthcare sector, along with the focus on early diagnosis and treatments to prevent the spread of different diseases, is another aspect leading to the increased adoption of medical imaging technologies in the region.
The Asia Pacific region is expected to experience the most substantial growth during the period forecast. It is due to the availability of government funds for developing pharmaceutical industries in the area. The market for pharmaceutical contract manufacturing in Asia-Pacific will experience the fastest growth due to the large population, low labor costs, relaxed regulations, abundant availability of raw materials, improved infrastructure, increased demand for generics, and increased production capacities.
Single-Photon Emission Computed Tomography Market Report Scope:
|Market Revenue in 2023||USD 2.97 Billion|
|Projected Forecast Revenue in 2032||USD 5.31 Billion|
|Growth Rate from 2023 to 2032||CAGR of 6.69%|
|Largest Market||North America|
|Forecast Period||2023 To 2032|
|Regions Covered||North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa|
Increasing research and development activities
Research and development activities explore new applications and clinical uses for SPECT imaging. By expanding the range of conditions and diseases that can be diagnosed and monitored using SPECT, researchers can create additional opportunities for the utilization of SPECT systems. This increased scope of applications can lead to higher demand for SPECT imaging, stimulating market growth. R&D efforts lead to technological advancements in SPECT imaging systems, including improvements in image quality, resolution, sensitivity, and acquisition speed. These advancements make SPECT a more reliable and efficient imaging modality, enhancing its diagnostic capabilities. As a result, healthcare providers are more likely to adopt SPECT systems, thereby driving market growth.
Availability of alternative imaging techniques
SPECT imaging requires specialized equipment and expertise, which may not be readily available in all healthcare facilities. This can result in limited access to SPECT imaging services, particularly in rural or underdeveloped areas. Patients in these regions may face challenges in accessing SPECT scans, leading to delayed or inadequate diagnosis and treatment. SPECT competes with other advanced imaging modalities such as positron emission tomography (PET) and magnetic resonance imaging (MRI). PET offers higher resolution and sensitivity, while MRI provides excellent anatomical detail. These alternative imaging techniques may be preferred in certain clinical scenarios, limiting the demand for SPECT scans.
Rising demand for improved diagnostic certainty and localization
The enhanced localization and diagnostic accuracy for a broad range of applications is the main benefit of SPECT/CT. The seamless capture of functional and anatomical imaging data results in additional benefits for patients and doctors. SPECT/CT reduces logistical delays, which enhances picture attenuation correction. The instantaneous accessibility of supplementary picture data is a benefit. As the awareness for early and raid diagnosis increases, the demand for improved diagnostic methods is growing simultaneously. This requirement in the healthcare sector is observed to offer a plethora of opportunities for the market by growing the implementation and application of SPECT systems.
The risk of inaccurate estimation of blood flow
The capacity of single photon emission computed tomography (SPECT) to detect multiple vessels and microvascular coronary artery disease is limited. Measuring myocardial flow reserve (MFR) and absolute myocardial blood flow (MBF) is possible using gamma cameras equipped with cadmium zinc telluride detectors. However, there is little to no proof of its repeatability and little evidence of its accuracy. So, the systems are sometimes prone to offer inaccurate estimation of blood flow, this element creates a challenge for the market’s growth by limiting the users’ acceptance of the technology.
Major Key Players:
Buy this Research Report@ https://www.precedenceresearch.com/checkout/2591
You can place an order or ask any questions, please feel free to contact at email@example.com | +1 9197 992 333